Health Care & Life Sciences » Biotechnology | Intellect Neurosciences Inc.

Intellect Neurosciences Inc. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2011
2012
2013
2014
2015
Sales/Revenue
-
6,500.00
-
-
1,200.00
SG&A Expense
3,531.90
6,216.20
4,347.70
1,137.20
2,090.60
EBIT
-
283.80
4,347.70
1,137.20
890.60
Unusual Expense
8,984.00
7,194.30
1,974.10
745.70
11,827.00
Interest Expense
4,370.70
3,421.80
6,681.90
13,168.60
5,231.20
Pretax Income
1,081.40
4,056.30
9,055.50
15,051.50
5,705.30
Consolidated Net Income
1,081.40
4,056.30
9,055.50
15,051.50
5,705.30
Net Income
1,081.40
4,056.30
9,055.50
15,051.50
5,705.30
Net Income After Extraordinaries
1,081.40
4,056.30
9,055.50
15,051.50
5,705.30
Net Income Available to Common
131.40
4,056.30
9,755.50
15,051.50
5,705.30
EPS (Basic)
0.18
1.70
17.87
11.77
0.05
Basic Shares Outstanding
117.90
324.00
545.90
1,279.00
2,528.10
EPS (Diluted)
0.18
1.70
17.87
11.77
0.05
Diluted Shares Outstanding
1,228.50
2,572.40
545.90
1,279.00
64,398.30
EBITDA
3,531.90
283.80
4,347.70
1,137.20
890.60
Preferred Dividends
950.00
-
700.00
-
-

About Intellect Neurosciences

View Profile
Address
550 Sylvan Avenue
Englewood Cliffs New Jersey 07632
United States
Employees -
Website http://www.intellectns.com
Updated 09/14/2018
Intellect Neurosciences, Inc. is a biopharmaceutical company, which is engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of neurodegenerative conditions, collectively known as proteinopathies, which include alzheimer's, parkinson's and huntington disease. The company was founded by Daniel G. Chain on April 25, 2005 and is headquartered in Englewood Cliffs, NJ.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.